Search

Your search keyword '"Steg, Ph. Gabriel"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Steg, Ph. Gabriel" Remove constraint Author: "Steg, Ph. Gabriel" Publisher elsevier bv Remove constraint Publisher: elsevier bv
90 results on '"Steg, Ph. Gabriel"'

Search Results

1. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: ODYSSEY OUTCOMES

2. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events

3. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes

5. Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

7. Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI

8. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

9. Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score : Data from THEMIS and THEMIS PCI

11. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT

12. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19

13. Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program

14. REDUCTION IN HEART FAILURE WITH ICOSAPENT ETHYL: INSIGHTS FROM REDUCE-IT HF

15. ICOSAPENT ETHYL REDUCES ISCHEMIC EVENTS IN PATIENTS WITH HIGH TRIGLYCERIDES AND LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS: REDUCE-IT HIGH TG/LOW HDL-C ANALYSES

16. Causes and Risk Factors for Death in Diabetes

17. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial

18. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

19. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT

20. Reply

21. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

23. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

24. Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial

25. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events

26. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial)

27. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials

28. Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events)

29. The Reply

30. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease

31. Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials

32. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)

35. Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease

37. “Off-Hours” Versus “On-Hours” Presentation in ST-Segment Elevation Myocardial Infarction

38. Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events

39. Reply

40. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial

41. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54

42. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease

44. Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding

46. Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST

47. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up

49. Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin

50. Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention

Catalog

Books, media, physical & digital resources